Individualized Hemodynamic Optimization by Indirect Measurement of the Respiratory Quotient in Major Surgery: Prospective Randomized Multicentre Open-Label Study (OPHIQUE) Individualized Optimization by Indirect Measurement of the Respiratory Quotient

Sponsor
Centre Hospitalier Universitaire, Amiens (Other)
Overall Status
Recruiting
CT.gov ID
NCT03852147
Collaborator
st isabelle health center, abbeville (Other), Centre Hospitalier Universitaire de Caen (Other), Centre Hospitalier VALENCIENNES (Other)
350
1
2
49
7.1

Study Details

Study Description

Brief Summary

The measurement of the inspired / expired fractions in O2 and CO2 is part of the daily monitoring of the intubated-ventilated patient in the operating theater. The ratio of VCO2 to VO2 (respiratory quotient (RQ)) is a non-invasive indirect measure of anaerobic metabolism of the patient, and an indirect reflection of tissue perfusion. We hypothesize that a hemodynamic optimization in major surgery individualized by non-invasive continuous measurement of the RQ would optimize TaO2 more specifically by informing us about the installation of a VO2 dependence, and therefore of an anaerobic metabolism. Patients are randomized in 2 groups : Control group: hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of Systolic Voume (SV) by vascular filling and use of dobutamine if necessary. Experimental group: perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine. Primary and secondary outcomes are recorded 1,2,7 and 30 days after the surgery.

Condition or Disease Intervention/Treatment Phase
  • Procedure: : hemodynamic management
N/A

Detailed Description

• Background : The measurement of the inspired / expired fractions in O2 and CO2 is part of the daily monitoring of the intubated-ventilated patient in the operating theater. Changes in EtCO2 may reflect changes in metabolic CO2 production (VCO2), and oxygen extraction from the body (SvO2). The inspired / exhaled oxygen difference is an indirect reflection of the oxygen consumption (VO2). The ratio of VCO2 to VO2 (respiratory quotient (RQ)) is a non-invasive indirect measure of anaerobic metabolism of the patient, and an indirect reflection of tissue perfusion.

Some studies, including a recent one carried out by our center, showed that the RQ was linked to the appearance of anaerobic metabolism and to the postoperative evolution of the patient. The RQ was correlated with arterial lactate levels and predicted the occurrence of postoperative complications. Thus, the RQ can be a reliable, continuous, non-invasive marker of anaerobic metabolism in the operating room and therefore of the adequacy of arterial oxygen Transport (TaO2) with respect to the VO2 of the patient

  • Purpose : Th investigators hypothesize that a hemodynamic optimization in major surgery individualized by non-invasive continuous measurement of the RQ would optimize TaO2 more specifically by informing us about the installation of a VO2 dependence, and therefore of an anaerobic metabolism.

  • Brief summary:

The measurement of the inspired / expired fractions in O2 and CO2 is part of the daily monitoring of the intubated-ventilated patient in the operating theater. The ratio of VCO2 to VO2 (respiratory quotient (RQ)) is a non-invasive indirect measure of anaerobic metabolism of the patient, and an indirect reflection of tissue perfusion. We hypothesize that a hemodynamic optimization in major surgery individualized by non-invasive continuous measurement of the RQ would optimize TaO2 more specifically by informing us about the installation of a VO2 dependence, and therefore of an anaerobic metabolism. Patients are randomized in 2 groups : Control group: hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of Systolic Voume (SV) by vascular filling and use of dobutamine if necessary. Experimental group: perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine. Primary and secondary outcomes are recorded 1,2,7 and 30 days after the surgery.

Number of groups and description of groups :

2 groups Control group: hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary.

Experimental group: perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine.

• Interventions : Control group: hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary.

Experimental group: perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine.

The primary outcome is defined by at least one organ failure within 7 days postoperatively.

The duration of participation of each patient is 30 days and total research term is 49 months

  • Number of subjects : 350

  • Statistical analysis : The null hypothesis will be rejected in favor of the alternative hypothesis (there is a difference) using a test of χ2 or a Fisher test according to the frequency of the complications with a risk of the first bilateral species of 5%.

  • Key-words : respiratory quotient, post opérative complications, anaerobic metabolism.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
350 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Individualized Hemodynamic Optimization by Indirect Measurement of the Respiratory Quotient in Major Surgery: Prospective Randomized Multicentre Open-Label Study (OPHIQUE) Individualized Optimization by Indirect Measurement of the Respiratory Quotient
Actual Study Start Date :
Dec 26, 2018
Anticipated Primary Completion Date :
Dec 26, 2022
Anticipated Study Completion Date :
Jan 26, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Control group

hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary.

Procedure: : hemodynamic management
Control group: hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary. Experimental group: perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine.

Experimental: Experimental group

perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine.

Procedure: : hemodynamic management
Control group: hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary. Experimental group: perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine.

Outcome Measures

Primary Outcome Measures

  1. organ failure [7 days postoperatively]

    at least one organ failure within 7 days postoperatively. • Organ failure is defined according to the recommendations of the European Anesthesia Society (ESA) and the European Resuscitation Society (ESICM).

Secondary Outcome Measures

  1. the length of stay in the hospital [30 days]

  2. the mortality at day 30 [30 days]

  3. the SOFA score at day1, day2, and day7 [7 days]

  4. total volume of fluid intraoperatively [30 days]

  5. Plasma creatinine measured on day 0, day 1, day 2 and day 7 postoperatively [7 days]

  6. Plasma lactate measured on day 1, day 2 and day 7 postoperatively [7 days]

  7. C Reactive protein measured on day1, day2 and day7 postoperative [7 days]

  8. Troponin Tc measured on day1, day2 and day7 postoperatively [7 days]

  9. (NT pro) Brain Natriuretic Peptide ((NT pro) BNP) measured at day1, day2 and day7 postoperative [7 days]

  10. the incidence of each complication [30 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Abdominal, orthopedic or vascular surgery with general anesthesia

  • ASA score ≥ II

  • Estimated duration of surgery> 2 hours

  • Consent signed.

  • Affiliation to a social security scheme

Exclusion Criteria:
  • Untreated or unbalanced severe hypertension under treatment.

  • Preoperative renal failure dialyzed.

  • Acute heart failure.

  • Acute coronary insufficiency.

  • Vascular surgery with kidney plasty.

  • Cardiac surgery.

  • Permanent laparoscopy.

  • Preoperative shock state.

  • Refusal of patient's participation

  • Pregnant woman, parturient or breastfeeding.

  • Patient under guardianship or trusteeship, under the protection of justice or private public law.

  • Anesthesia with loco-regional anesthesia (spinal anesthesia and epidural).

  • Acute respiratory distress syndrome (PaO2 / FiO2 ratio <300).

  • Chronic Respiratory Failure with Home Oxygen Therapy.

  • Patient already included in another therapeutic trial with an experimental molecule.

  • Emergency anesthesia

Contacts and Locations

Locations

Site City State Country Postal Code
1 BAR Amiens France 80054

Sponsors and Collaborators

  • Centre Hospitalier Universitaire, Amiens
  • st isabelle health center, abbeville
  • Centre Hospitalier Universitaire de Caen
  • Centre Hospitalier VALENCIENNES

Investigators

  • Principal Investigator: Stéphane Bar, Dr, CHU Amiens

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Universitaire, Amiens
ClinicalTrials.gov Identifier:
NCT03852147
Other Study ID Numbers:
  • PI2018_843_0014
First Posted:
Feb 25, 2019
Last Update Posted:
Feb 25, 2019
Last Verified:
Feb 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Universitaire, Amiens
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 25, 2019